Corpus GrippeAllemagneV3

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

[Pandemic 2009/10: reflections on the utility of the vaccination actions in Hesse].

Identifieur interne : 000152 ( Main/Exploration ); précédent : 000151; suivant : 000153

[Pandemic 2009/10: reflections on the utility of the vaccination actions in Hesse].

Auteurs : H. Uphoff ; A. Wirtz ; K. Jahn ; A M Hauri

Source :

RBID : pubmed:23757105

Descripteurs français

English descriptors

Abstract

In the state of Hesse (Germany) all vaccinations were administered either by the public health-care (ÖGD) or private health-care facilities and were registered by week and age group. In the following article, the benefit of the vaccination campaign will be looked at in terms of preventable consultations due to acute respiratory tract infections (AK-ARI). AK-ARI were registered with the nation-wide sentinel of the AGI. Scenarios regarding timing and age-specific coverage are modelled. The achieved timing and age distribution was compared to assumed ideal distributions, e. g., having achieved the final coverage 2 weeks before epidemic start or having applied the used vaccine exclusively for the most affected age group 5-14 years. The timing and coverage actually achieved (7% overall) prevented an estimated 1.4% or, respectively, 1.1% of the total consultation excess. With the same amount of vaccine but ideally applied at least 2 weeks -before the begin of the epidemic and exclusively to the age group of the 5- to 14-year olds, an estimated 13.9% or, respectively, 18.2% of the total excess could have been prevented. The simulated scenarios give estimations as to what benefit potentially could have been achieved during the A(H1N1)pdm09 pandemic. Both the delayed successive access to vaccine and the not ideal age distribution reduced the benefit to about 30% of the optimum. These exemplary estimates underline the importance of timeliness and valid prioritising of vaccination campaigns, although footing on just one outcome. It appears beneficial to reduce uncertainties for a solid prioritisation by, e. g., timely extended surveillance. Short-term decisions and adoptions are likely for future campaigns, e. g., due to unexpected changes in the epidemic, demanding flexibility in the application management.

DOI: 10.1055/s-0033-1343432
PubMed: 23757105


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">[Pandemic 2009/10: reflections on the utility of the vaccination actions in Hesse].</title>
<author>
<name sortKey="Uphoff, H" sort="Uphoff, H" uniqKey="Uphoff H" first="H" last="Uphoff">H. Uphoff</name>
<affiliation>
<nlm:affiliation>Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen (HLPUG).</nlm:affiliation>
<wicri:noCountry code="no comma">Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen (HLPUG).</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Wirtz, A" sort="Wirtz, A" uniqKey="Wirtz A" first="A" last="Wirtz">A. Wirtz</name>
<affiliation>
<nlm:affiliation>Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen (HLPUG).</nlm:affiliation>
<wicri:noCountry code="no comma">Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen (HLPUG).</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Jahn, K" sort="Jahn, K" uniqKey="Jahn K" first="K" last="Jahn">K. Jahn</name>
<affiliation>
<nlm:affiliation>Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen (HLPUG).</nlm:affiliation>
<wicri:noCountry code="no comma">Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen (HLPUG).</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Hauri, A M" sort="Hauri, A M" uniqKey="Hauri A" first="A M" last="Hauri">A M Hauri</name>
<affiliation>
<nlm:affiliation>Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen (HLPUG).</nlm:affiliation>
<wicri:noCountry code="no comma">Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen (HLPUG).</wicri:noCountry>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:23757105</idno>
<idno type="pmid">23757105</idno>
<idno type="doi">10.1055/s-0033-1343432</idno>
<idno type="wicri:Area/Main/Corpus">000193</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000193</idno>
<idno type="wicri:Area/Main/Curation">000193</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000193</idno>
<idno type="wicri:Area/Main/Exploration">000193</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">[Pandemic 2009/10: reflections on the utility of the vaccination actions in Hesse].</title>
<author>
<name sortKey="Uphoff, H" sort="Uphoff, H" uniqKey="Uphoff H" first="H" last="Uphoff">H. Uphoff</name>
<affiliation>
<nlm:affiliation>Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen (HLPUG).</nlm:affiliation>
<wicri:noCountry code="no comma">Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen (HLPUG).</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Wirtz, A" sort="Wirtz, A" uniqKey="Wirtz A" first="A" last="Wirtz">A. Wirtz</name>
<affiliation>
<nlm:affiliation>Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen (HLPUG).</nlm:affiliation>
<wicri:noCountry code="no comma">Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen (HLPUG).</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Jahn, K" sort="Jahn, K" uniqKey="Jahn K" first="K" last="Jahn">K. Jahn</name>
<affiliation>
<nlm:affiliation>Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen (HLPUG).</nlm:affiliation>
<wicri:noCountry code="no comma">Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen (HLPUG).</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Hauri, A M" sort="Hauri, A M" uniqKey="Hauri A" first="A M" last="Hauri">A M Hauri</name>
<affiliation>
<nlm:affiliation>Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen (HLPUG).</nlm:affiliation>
<wicri:noCountry code="no comma">Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen (HLPUG).</wicri:noCountry>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany))</title>
<idno type="eISSN">1439-4421</idno>
<imprint>
<date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Female</term>
<term>Germany (epidemiology)</term>
<term>Health Promotion (statistics & numerical data)</term>
<term>Humans</term>
<term>Incidence</term>
<term>Infant</term>
<term>Infant, Newborn</term>
<term>Influenza Vaccines (therapeutic use)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Male</term>
<term>Mass Vaccination (statistics & numerical data)</term>
<term>Middle Aged</term>
<term>Pandemics (prevention & control)</term>
<term>Pandemics (statistics & numerical data)</term>
<term>Prevalence</term>
<term>Treatment Outcome</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Allemagne (épidémiologie)</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Femelle</term>
<term>Grippe humaine ()</term>
<term>Grippe humaine (épidémiologie)</term>
<term>Humains</term>
<term>Incidence</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Nourrisson</term>
<term>Nouveau-né</term>
<term>Pandémies ()</term>
<term>Promotion de la santé ()</term>
<term>Prévalence</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Vaccination de masse ()</term>
<term>Vaccins antigrippaux (usage thérapeutique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en">
<term>Germany</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en">
<term>Influenza, Human</term>
<term>Pandemics</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en">
<term>Health Promotion</term>
<term>Mass Vaccination</term>
<term>Pandemics</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr">
<term>Allemagne</term>
<term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Female</term>
<term>Humans</term>
<term>Incidence</term>
<term>Infant</term>
<term>Infant, Newborn</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Prevalence</term>
<term>Treatment Outcome</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Femelle</term>
<term>Grippe humaine</term>
<term>Humains</term>
<term>Incidence</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Nourrisson</term>
<term>Nouveau-né</term>
<term>Pandémies</term>
<term>Promotion de la santé</term>
<term>Prévalence</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Vaccination de masse</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">In the state of Hesse (Germany) all vaccinations were administered either by the public health-care (ÖGD) or private health-care facilities and were registered by week and age group. In the following article, the benefit of the vaccination campaign will be looked at in terms of preventable consultations due to acute respiratory tract infections (AK-ARI). AK-ARI were registered with the nation-wide sentinel of the AGI. Scenarios regarding timing and age-specific coverage are modelled. The achieved timing and age distribution was compared to assumed ideal distributions, e. g., having achieved the final coverage 2 weeks before epidemic start or having applied the used vaccine exclusively for the most affected age group 5-14 years. The timing and coverage actually achieved (7% overall) prevented an estimated 1.4% or, respectively, 1.1% of the total consultation excess. With the same amount of vaccine but ideally applied at least 2 weeks -before the begin of the epidemic and exclusively to the age group of the 5- to 14-year olds, an estimated 13.9% or, respectively, 18.2% of the total excess could have been prevented. The simulated scenarios give estimations as to what benefit potentially could have been achieved during the A(H1N1)pdm09 pandemic. Both the delayed successive access to vaccine and the not ideal age distribution reduced the benefit to about 30% of the optimum. These exemplary estimates underline the importance of timeliness and valid prioritising of vaccination campaigns, although footing on just one outcome. It appears beneficial to reduce uncertainties for a solid prioritisation by, e. g., timely extended surveillance. Short-term decisions and adoptions are likely for future campaigns, e. g., due to unexpected changes in the epidemic, demanding flexibility in the application management. </div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">23757105</PMID>
<DateCompleted>
<Year>2015</Year>
<Month>04</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>12</Month>
<Day>03</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1439-4421</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>76</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany))</Title>
<ISOAbbreviation>Gesundheitswesen</ISOAbbreviation>
</Journal>
<ArticleTitle>[Pandemic 2009/10: reflections on the utility of the vaccination actions in Hesse].</ArticleTitle>
<Pagination>
<MedlinePgn>48-55</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0033-1343432</ELocationID>
<Abstract>
<AbstractText>In the state of Hesse (Germany) all vaccinations were administered either by the public health-care (ÖGD) or private health-care facilities and were registered by week and age group. In the following article, the benefit of the vaccination campaign will be looked at in terms of preventable consultations due to acute respiratory tract infections (AK-ARI). AK-ARI were registered with the nation-wide sentinel of the AGI. Scenarios regarding timing and age-specific coverage are modelled. The achieved timing and age distribution was compared to assumed ideal distributions, e. g., having achieved the final coverage 2 weeks before epidemic start or having applied the used vaccine exclusively for the most affected age group 5-14 years. The timing and coverage actually achieved (7% overall) prevented an estimated 1.4% or, respectively, 1.1% of the total consultation excess. With the same amount of vaccine but ideally applied at least 2 weeks -before the begin of the epidemic and exclusively to the age group of the 5- to 14-year olds, an estimated 13.9% or, respectively, 18.2% of the total excess could have been prevented. The simulated scenarios give estimations as to what benefit potentially could have been achieved during the A(H1N1)pdm09 pandemic. Both the delayed successive access to vaccine and the not ideal age distribution reduced the benefit to about 30% of the optimum. These exemplary estimates underline the importance of timeliness and valid prioritising of vaccination campaigns, although footing on just one outcome. It appears beneficial to reduce uncertainties for a solid prioritisation by, e. g., timely extended surveillance. Short-term decisions and adoptions are likely for future campaigns, e. g., due to unexpected changes in the epidemic, demanding flexibility in the application management. </AbstractText>
<CopyrightInformation>© Georg Thieme Verlag KG Stuttgart · New York.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Uphoff</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen (HLPUG).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wirtz</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen (HLPUG).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jahn</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen (HLPUG).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hauri</LastName>
<ForeName>A M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo>
<Affiliation>Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen (HLPUG).</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>ger</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<VernacularTitle>Pandemie 2009/10: Betrachtungen zum Nutzen der Impfaktion in Hessen.</VernacularTitle>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>06</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Gesundheitswesen</MedlineTA>
<NlmUniqueID>9204210</NlmUniqueID>
<ISSNLinking>0941-3790</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005858" MajorTopicYN="N">Germany</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006293" MajorTopicYN="N">Health Promotion</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D032541" MajorTopicYN="N">Mass Vaccination</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2013</Year>
<Month>6</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2013</Year>
<Month>6</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2015</Year>
<Month>4</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">23757105</ArticleId>
<ArticleId IdType="doi">10.1055/s-0033-1343432</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations>
<list></list>
<tree>
<noCountry>
<name sortKey="Hauri, A M" sort="Hauri, A M" uniqKey="Hauri A" first="A M" last="Hauri">A M Hauri</name>
<name sortKey="Jahn, K" sort="Jahn, K" uniqKey="Jahn K" first="K" last="Jahn">K. Jahn</name>
<name sortKey="Uphoff, H" sort="Uphoff, H" uniqKey="Uphoff H" first="H" last="Uphoff">H. Uphoff</name>
<name sortKey="Wirtz, A" sort="Wirtz, A" uniqKey="Wirtz A" first="A" last="Wirtz">A. Wirtz</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeAllemagneV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000152 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000152 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    GrippeAllemagneV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:23757105
   |texte=   [Pandemic 2009/10: reflections on the utility of the vaccination actions in Hesse].
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:23757105" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeAllemagneV3 

Wicri

This area was generated with Dilib version V0.6.35.
Data generation: Tue Jul 7 11:47:10 2020. Site generation: Sat Sep 26 09:55:33 2020